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Because the rupture risk of untreated aneurysms of the 
descending thoracic aorta is so pronounced,1 a policy of 
repairing descending thoracic aortic aneurysms (DTAA) is 
advocated even in the very elderly. The introduction of 
endovascular technology allowed the treatment of aortic 
diseases with lower risk of early mortality and morbidity 
compared with open surgical repair.2 However, compara-
tive analyses of these 2 treatment strategies were based on 
small series and were not adjusted for differences between 
the surgical and endovascular populations.3–9 Still, the 
results suggest that endovascular repair may provide bet-
ter immediate outcome with midterm results that are not 
inferior to open surgery.3–9
A major limitation of current studies evaluating the 
safety and efficacy of thoracic endovascular aortic repair 
(TEVAR) is that only infrequently were they focused solely 
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Abstract
Purpose: To determine the efficacy of thoracic endovascular aortic repair (TEVAR) for degenerative aneurysm involving only 
the descending thoracic aorta (DTAA). Methods: An English-language literature review was performed through PubMed, 
Scopus, and Google Scholar to identify any study evaluating the outcomes of TEVAR for DTAA. The main endpoints of 
this analysis were all-cause 30-day and late postoperative mortality. Secondary outcome measures were procedure success, 
vascular access complications, paraplegia, stroke, early endoleaks during the index hospitalization, aneurysm-related death, 
reinterventions, and conversion to open repair. To control for the anticipated heterogeneity among small observational studies, 
absolute values and means were pooled using random effects models; the results are expressed as pooled proportions, means, 
or risk ratio (RR) with 95% confidence intervals (CIs). Results: Eleven studies reporting on 673 patients (mean age 72.6 years, 
mean aneurysm diameter 62.9 cm) with DTAA were selected for the analysis. Technical success was reported in 91.0% of 
patients, and vascular access complications requiring repair were encountered in 9.7% of cases. Pooled overall 30-day, 1-year, 
2-year, and 3-year survival rates were 96.0%, 80.3%, 77.3%, and 74.0%, respectively. Five studies compared the results of 
TEVAR after elective (n=151) and urgent/emergent procedure (n=77); the latter was a predictor of 30-day mortality (17.1% vs 
1.8%, RR 3.83, 95% CI 1.18 to 12.40, p=0.025). Paraplegia occurred in 3.2% of patients and was permanent in 1.4% of patients. 
The stroke rate was 2.7%. Early type I endoleak was observed in 7.3%, type II endoleak in 2.0%, and type III in 1.2% of patients. 
The mean follow-up of 9 studies was 22.3 months. At 3 years, freedom from reintervention was 90.3%. Death secondary to 
aneurysm rupture and/or fistula was reported in 3.2% of patients. Conclusion: Current results indicate that TEVAR for DTAA 
can be performed with rather high technical success, low postoperative morbidity, and good 3-year survival.
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on atherosclerotic degenerative aneurysms involving the 
descending thoracic aorta. Furthermore, most of the studies 
also included patients with aneurysms involving the aortic 
arch and/or the abdominal aorta, whose treatment is 
expected to be more complex and risky. This void in the 
literature has clinical implications because DTAA most 
often affects the very elderly, whereas aortic dissection and 
blunt aortic trauma are more often observed in younger 
patients.10 The present study was planned to pool the imme-
diate and late outcome data after TEVAR for DTAA alone 
in order to evaluate the efficacy and durability of endovas-




An English-language literature review was performed 
through PubMed, Scopus, and Google Scholar on July 15, 
2015, to identify any study evaluating the outcome of 
TEVAR for degenerative aneurysms involving the descend-
ing thoracic aorta. The search terms were “endovascular,” 
“descending,” “thoracic,” “stent-graft,” and “aneurysm.” 
The guidelines for Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) were applied.11 
Three authors (F.B., S.M., G.M.) independently reviewed 
the abstracts and articles. Reference lists in the retrieved 
articles were searched.
Treatment Definition and Inclusion/Exclusion 
Criteria
For the purpose of this study, TEVAR was considered any 
stent-graft procedure for treatment of degenerative aneurysm 
involving only the DTA where the stent-graft was deployed 
in Ishimaru landing zones 2 to 412 without covering the celiac 
axis. Patients who underwent carotid-subclavian bypass were 
eligible, but patients who underwent any other proximal de-
branching procedure were not. Similarly, patients with thora-
coabdominal aortic aneurysm, acute or chronic aortic 
dissection, penetrating atherosclerotic ulcer, blunt trauma, or 
any distal debranching procedure were ineligible.
Each study was independently evaluated by all coau-
thors for inclusion or exclusion from this analysis. To enter 
this analysis, studies had to (1) provide detailed baseline, 
operative, and outcome data of patients who underwent 
TEVAR for DTAA, (2) be a prospective or retrospective 
observational investigation of ≥20 adult patients, (3) be 
published in the English language as a full article after 
1999, and (4) report on at least immediate postoperative 
mortality. The language of the articles was defined as 
reported in PubMed. Data from abstracts or unpublished 
material were not included.
Articles were ineligible for analysis if they (1) reported 
ambiguous or inaccurate data (discrepancies between the 
text and tables); (2) had no information on baseline charac-
teristics, treatment modality, need and extent of debranch-
ing procedure, or data on the primary endpoint; (3) derived 
data from administrative databases; or (4) reported mixed 
data on TEVAR for aneurysms other than those solely in the 
DTA.
Data Extraction
Data were retrieved only from the articles, and no attempt 
was made to obtain specific or missing data from the 
authors. The following data were extracted: first author, 
year of publication, study period, study design, number of 
patients, gender, aneurysm size, major comorbidities, prox-
imal and distal landing zones, debranching procedures, use 
of prophylactic cerebrospinal fluid (CSF) drainage, proce-
dure success, number of stent-graft devices implanted, 
30-day mortality, paraplegia, stroke, types of early endo- 
leaks, length of follow-up, overall survival, aneurysm-
related deaths, reinterventions, and conversions to open 
repair.
Outcome Measures
The main endpoints of this analysis were all-cause 30-day 
and late postoperative mortality. Secondary outcome mea-
sures were procedure success, vascular access complica-
tions, paraplegia, stroke, endoleak during the index 
hospitalization, aneurysm-related death, reinterventions, 
and conversion to open repair. Definitions for these end-
points were those adopted by the investigators of the 
included studies. Aneurysm-related death included any 
mortality related directly to the aneurysm, such as rupture 
or fistula, ascertained at the time of treatment or at autopsy.
Statistical Analysis
To control for the anticipated heterogeneity among small 
observational studies, absolute values and means were 
pooled using random effects models; the results are 
expressed as pooled proportions or means with 95% confi-
dence intervals (CIs). Analysis of time-to-event outcome 
endpoints was performed by calculating the number of 
patients at risk from available survival curves and tables 
using a spreadsheet developed by Tierney and collabora-
tors.13 Heterogeneity across studies was evaluated using the 
I2 test. The quality of the included studies was assessed using 
the National Heart, Blood, and Lung Institute (NHBLI) cri-
teria for study quality assessment of cases series (http://
www.nhlbi.nih.gov/health-pro/guidelines/in-develop/car-
diovascular-risk-reduction/tools/). Sensitivity analysis and 
meta-regression were performed to evaluate the impact of 
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covariates on the development of postoperative stroke. 
p<0.05 was considered statistically significant. Statistical 
analysis was performed using the open access software 
Open Meta-Analyst (Brown University, Providence, RI, 
USA; http://www.cebm.brown.edu/openmeta/)
Results
Figure 1 summarizes the results of the literature search. 
Eleven studies reporting on 673 patients with DTAA were 
included in this meta-analysis.7,9,14–22 Characteristics of 
these studies are summarized in Table 1. Patients undergo-
ing TEVAR had a mean age of 72.6 years, and their mean 
maximum aneurysm diameter was 62.9 mm (Table 2). 
There was a high prevalence of coronary artery disease 
(46.8%) and chronic obstructive pulmonary disease 
(38.4%). The stent-graft was deployed into Ishimaru zone 
2 in 14.1% of cases, and debranching procedures for revas-
cularization of the left subclavian artery (LSA) were per-
formed in 14.1% of patients. A mean 1.8 stent-grafts was 
deployed in procedures with a mean duration of 146 min-
utes. Eight of 11 studies were of good quality as assessed 
by the NHBLI criteria.
Table 3 summarizes the pooled immediate and late out-
come after TEVAR. Technical success was reported in 
91.0% of patients, and vascular access complications 
requiring repair were encountered in 9.7% of cases. Type I 
endoleak was observed early after TEVAR in 7.3%, type II 
endoleak in 2.0%, and type III in 1.2% of patients.
Pooled overall 30-day mortality was 4.0% (95% CI 2.0 
to 6.0, I2=42%). Five studies compared the results of 
TEVAR after elective (n=151) and urgent/emergent proce-
dures (n=77); the latter was a predictive factor for 30-day 
mortality [17.1% vs 1.8%, risk ratio (RR) 3.83, 95% CI 
1.18 to 12.40, p=0.025]. Nine studies provided data on at 
least 1-year survival based on a mean follow-up of 22.3 
months. Pooled overall 1-, 2-, and 3-year survival rates 
were 80.3%, 77.3%, and 74.0%, respectively (Table 3, 
Figure 2). Death secondary to aneurysm rupture and/or fis-
tula was reported in 3.2% of patients.
Paraplegia occurred in 3.2% of patients and was perma-
nent in 1.4%. In 2 (8.7%) of 23 cases, postoperative para-
plegia was reversed by blood pressure management and 
CSF drainage.14,18 Data on CSF drainage were reported in 
only 5 studies; this neuroprotective method was employed 
in 30.6% of 305 patients.
Five studies evaluated the risk of stroke with and with-
out coverage of the LSA. The stroke rate was 2.7%. LSA 
Figure 1. Flowchart of the literature search.
Table 1. Characteristics of Studies Evaluating Outcomes After Endovascular Treatment for Degenerative Aneurysm of the 
Descending Thoracic Aorta.











Neuhauser, 2004, Austria 1997–2003 R Fair 31 58 Mixed 26/74 3
Makaroun, 2005, USA 1999–2001 P Good 139 100 Gore TAG 20/80 20
Glade, 2005, Netherlands 1999–2003 R Good 42 83 Mixed 0/100 0
Marcheix, 2006, France 1996–2005 P Good 45 82 Mixed 13/87 0
Appoo, 2006, USA 1999–2005 P Good 99 — Mixed 20/80 20
Cambria, 2009, USA 2005–2007 P Good 20 0 Gore TAG 0/100 0
Hughes, 2010, USA 2005–2009 R Fair 79 30 Mixed 42/58 5
Desai, 2012, USA 1995–2007 P Good 106 92 Mixed 20/81 17
Yunoki, 2014, Japan 2008–2011 R Good 36 100 Gore TAG 0/100 0
Saratzis, 2007, Greece 2003–2005 R Fair 23 100 EndoFit 0/23 0
Saari, 2013, Finland 1998–2010 R Good 53 77 Mixed 9/44 8
Abbreviations: P, prospective; R, retrospective.
aQuality of these studies was assessed by the National Heart, Blood, and Lung Institute criteria for quality assessment of case series.
bData are given as the percentages.
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coverage was associated with a trend toward increased 
risk of stroke (pooled rates: 4.8% vs 3.1%, RR 2.26, 95% 
CI 0.40 to 12.46, p=0.350). The risk of stroke was not 
increased either by the proportion of coverage of the LSA 
(p=0.517) or the proportion of debranching procedures 
(p=0.317).
Table 2. Pooled Baseline and Operative Characteristics of 673 Patients Who Underwent Endovascular Treatment for Degenerative 
Aneurysm of the Descending Thoracic Aorta.
Variables Pooled Proportion, %a Meana Studies, n Patients, n I2, %
Age, y 72.6 (71.3 to 73.9) 9 608 59
Women 29.9 (15.8 to 43.9) 8 566 94
CAD 46.8 (34.4 to 59.1) 10 631 91
CVD 10.7 (7.8 to 13.6) 7 441  0
COPD 38.4 (27.9 to 48.9) 11 673 89
Aneurysm diameter, mm 62.9 (60.4 to 65.3) 9 547 69
Prior aortic procedure 22.2 (1.0 to 34.7) 6 321 90
Elective procedure 72.4 (55.1 to 89.6) 10 574 99
Ishimaru landing zones 11 673  
 2 14.1 (7.6 to 20.7) — — 91
 3/4 86.0 (79.5 to 92.6) — — 91
LSA coverage 14.1 (7.6 to 20.7) 11 673 91
Debranching procedure 7.3 (3.4 to 11.3) 11 673 85
CSF drainage 30.6 (8.1 to 53.0) 5 305 97
Procedure duration, min 146 (111 to 181) 5 290 95
No. of devices implanted 1.8 (1.6 to 2.1) 11 673 97
Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CSF, cerebrospinal fluid; CVD, cerebrovascular disease; 
LSA, left subclavian artery.
aData are given with the 95% confidence interval in parentheses.
Table 3. Outcomes After Endovascular Treatment for Degenerative Aneurysm of the Descending Thoracic Aorta.
Outcome Measure Pooled Proportion, %a Meana Studies, n Patients, nb I2, %
Mortality at 30 days 4.0 (2.0 to 6.0) 11 673 42
Technical success 91.0 (86.1 to 95.9) 10 426 91
Access complications requiring repair 9.7 (4.1 to 15.2) 8 435 80
Paraplegia 3.2 (1.9 to 4.5) 11 673  0
Permanent paresis 1.4 (0.6 to 2.3) 11 673  0
Stroke 2.7 (1.5 to 3.9) 11 673  0
Early endoleaks  
 Type I 7.3 (3.5 to 11.1) 10 567 78
 Type II 2.0 (0.8 to 3.2) 10 567  5
 Type III 1.2 (0.2 to 2.3) 10 567 23
Early or late reintervention 9.6 (6.5 to 12.7) 11 673 45
Early or late surgical reoperation 1.4 (0.5 to 2.2) 10 653  0
Aneurysm rupture/fistula-related death 3.2 (1.2 to 5.2) 9 525 42
Length of follow-up, mo 22.3 (17.7 to 27.0) 9 468 89
Survival  
 1-year 80.3 (72.2 to 88.4) 9 545 88
 2-year 77.3 (69.4 to 85.4) 8 457 76
 3-year 74.0 (65.3 to 82.7) 6 277 62
Freedom from reintervention  
 1-year 93.4 (89.3 to 97.5) 5 279 50
 2-year 91.8 (87.6 to 96.1) 5 224 28
 3-year 90.3 (85.3 to 95.4) 5 153 15
aData are given with the 95% confidence interval in parentheses.
bThe number of patients at risk at each follow-up interval was estimated using the method of Tierney et al.13
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Reintervention for complications after TEVAR was 
required in 9.6% of patients, with a freedom from reopera-
tion of 90.3% at 3 years (Table 3, Figure 2). Open surgical 
reoperation was needed in 1.4% of patients.
Discussion
DTAA is a life-threatening condition in which the yearly rup-
ture risk of aneurysms >6 cm can exceed 10% in the elderly, 
particularly in the presence of pulmonary disease and chest 
pain.1 Elefteriades23 estimated that the yearly risk of rupture, 
dissection, or death of patients with any thoracic aneurysm 
>6 cm is about 14%. Although open surgery can be consid-
ered the standard procedure with a low risk of late complica-
tions, it is a major procedure associated with significant risk 
of mortality and morbidity.2 TEVAR seems to be associated 
with excellent early results compared with open surgery 
despite a somewhat higher risk profile of patients undergoing 
endovascular procedures. These results, as well as its less 
invasive nature, are reasonable arguments in favor of TEVAR, 
particularly in the treatment of DTAAs in the elderly. Any 
less invasive procedure carrying a lower risk of morbidity 
should be preferred in fragile, elderly patients. Indeed, an 
interventional policy that does not consider the high risk of 
postoperative morbidity associated with major cardiovascu-
lar surgery in the elderly can still achieve satisfactory postop-
erative survival, but with high social costs and poor quality of 
life in a number of survivors.24
The present pooled analysis indicates that TEVAR is a valid 
treatment in elderly patients with degenerative atherosclerotic 
aneurysm involving only the descending thoracic aorta. The 
study population was rather old and with high prevalence of 
coronary artery and pulmonary diseases. Importantly, one third 
of these patients underwent urgent/emergency procedures, 
which was associated with a significantly increased risk of 
mortality. However, elective TEVAR was associated with a 
<2% 30-day mortality, which can be considered excellent. 
Although 3-year pooled survival was 74%, it is worth noting 
that about 20% of patients had died by the 1-year follow-up. 
This figure can be partly explained by the high mortality in 
patients undergoing urgent/emergency operation. Furthermore, 
suboptimal intermediate survival was due to the poor health 
status suggested by the high prevalence of comorbidities.
The incidence of paraplegia was low, particularly when 
one considers that CSF drainage was used in a limited num-
ber of patients. It is likely that prophylactic neuroprotective 
strategies should be considered more frequently, particularly 
in patients undergoing coverage of the LSA and/or of the 
lowest third of the descending thoracic aorta, as well as in the 
setting of previous abdominal aortic aneurysm repair.16–18
TEVAR was performed in this series with a pooled technical 
success of 91% and a 7% incidence of early type I endoleak, 
which likely may be even lower with the use of newer devices.18 
This translated into a 90% freedom from aortic reintervention at 
3 years. The low proportion of patients with early and late aneu-
rysm rupture/fistula-related mortality could be underestimated 
owing to the lack of autopsy data in all deceased patients.
About 10% of the population had vascular access compli-
cations requiring surgical or endovascular repair. Such com-
plications are likely to decrease in the future with the 
increasing experience and technological development of 
TEVAR devices. However, all efforts should be made to 
avoid major vascular complications as the experience with 
transcatheter aortic valve replacement has shown that these 
sequelae can be associated with a significantly increased risk 
of mortality and morbidity, as well as incremental costs.25,26
Limitations
The major pitfall of the included studies was the rather short 
follow-up. In a few studies, the potential follow-up could have 
been almost 10 years,9 but still the authors did not provide data 
with enough long-term follow-up. This is a critical issue as 
these elderly patients, despite their comorbidities, may still 
have a rather long life expectancy as suggested by the 3-year 
pooled survival in this analysis. Longevity may favor the evo-
lution of aneurysm disease as well as stent-graft fatigue. Six 
studies were retrospective and most of the studies failed to pro-
vide details on their methods of follow-up. The latter is a major 
shortcoming in the assessment of these high-risk patients as it 
may easily lead to overestimation of the survival outcome.
Autopsy was not performed in all patients who died sud-
denly, which may result in an underestimation of aneurysm-
related events. In fact, a recent multicenter study performed in 
Finland,22 where the autopsy rate is rather high and follow-up 
data are easy to collect, showed poorer 3-year survival (57%) 
and freedom from aneurysm-related death (89%).
Seven of 11 series included patients treated during the 
1990s, which means that current results could be even 
Figure 2. Pooled survival and freedom from aortic 
reintervention after endovascular treatment for degenerative 
aneurysm involving only the descending aorta.
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better than represented in these pooled data as a result of 
significant improvements in stent-graft technology along 
with accumulated experience in major endovascular 
procedures.18
Conclusion
There are limited data on the long-term outcome after 
TEVAR, which prevents conclusive opinions on the dura-
bility of this treatment. However, the available data showed 
that TEVAR for DTAA is safe and associated with rather 
low early mortality and morbidity risk. Pooled 3-year sur-
vival of these patients appeared to be satisfactory.
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